Developer docs
API playgroundTry for free, no card

Search company profiles

Neurochase

Full company profile

uuid000apb3

Namestring
Neurochase
Legal namestring
Neurochase Limited
Websiteurl
neurochase.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Neurochase Limited is a privately held UK medical-device company, founded in 2020 and headquartered in Cardiff with operational offices in Bristol and Glasgow, that develops and licenses Convection Enhanced Delivery (CED) platforms for targeted delivery of gene, cell and conventional therapies to the central nervous system. Its core product line centres on proprietary CED micro-catheters that use a pressure gradient to drive therapeutics past the blood-brain barrier and distribute them homogeneously through interstitial brain tissue, with cannula insertion achievable within 10 minutes per cannula and reflux control designed for accurate dosing. The platform is complemented by specialised electrospun micro-catheters manufactured in partnership with VIVOLTA using the MediSpin production system, and by the Neuroinfuse drug delivery system — a bone-anchored transcutaneous port acquired from Renishaw Neuro Solutions in November 2025 that enables intermittent, chronic therapy administration over months or years to deep brain targets.

The company monetises through three streams: licensing of its CED drug delivery technology and devices to pharmaceutical and biotech partners for use in their CNS clinical programs, expert consultancy on protocol development, surgical workflow optimisation and surgeon training for both preclinical studies and clinical trials, and future device sales for clinical trial use beginning in 2025. Its customer base consists of pharma and biotech sponsors developing gene and cell therapies for Parkinson's, Huntington's, MND/ALS, drug-resistant epilepsy, brain tumours and dementia, plus supporting CROs; named partners include Spark Therapeutics (Roche), CombiGene, Innervate Therapeutics, Hamlet Pharma and AviadoBio.

Neurochase is led by Founder and CSO Prof. Steven Gill, a pioneer of deep brain stimulation and the first clinical trial infusing GDNF directly into the brain, alongside CEO Sharon Kane, Medical Director Neil Barua and Chief Marketing Officer Jacqueline Keller. The company cites over 5,000 catheter infusions delivered to humans, a Phase 2 Parkinson's trial demonstrating neuro-restoration, and doubled progression-free survival in DIPG brainstem cancer as evidence of clinical credibility supporting its £1.5B addressable market claim for CNS drug delivery.

Short descriptiontext

Neurochase is a UK privately-held medical-device company that develops and licenses Convection Enhanced Delivery (CED) systems — proprietary micro-catheters and a bone-anchored port — to enable pharmaceutical and biotech partners to deliver gene, cell and conventional therapies across the blood-brain barrier for CNS disorders.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBristol, United Kingdom
HQ citystring
Bristol
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
CNS drug delivery, Convection Enhanced Delivery, Medical device manufacturing, Neuroscience consulting services, Micro-catheter production
Industry1 code
PRIMARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Surgical and Medical Instrument Manufacturing339112
SIC code2 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Surgical & Medical Instruments & Apparatus3841
Product category
CNS Drug Delivery Medical Devices
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Drug Delivery Device Licensing
TypeLicensing Royalties
Description

Neurochase licenses its proprietary CED drug delivery technology and devices to pharmaceutical and biotech companies for use in their clinical programs. The company provides access to its technology platform including micro-catheters and delivery systems.

neurochase.com
2Consultancy Services
TypeProfessional Services
Description

Expert consultancy to biotech and pharma on direct delivery of therapies to the CNS. Services include protocol development, surgical workflow optimisation, and surgeon training. Pre-clinical support includes stereotactic equipment, devices and training to CROs.

neurochase.com
3Device Sales
TypeHardware Sales
Description

Sale and supply of CED drug delivery devices for clinical trials. From 2025, access to CED devices for clinical trial use. The company planned clinical trial for early 2026 using Neuroinfuse system.

neurochase.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Neurochase develops and licenses proprietary Convection Enhanced Delivery (CED) technology for targeted intraparenchymal drug delivery to the central nervous system. Its flagship platform uses micro-catheters with pressure gradient-driven convection to push therapeutics through interstitial space, enabling homogeneous distribution past the blood-brain barrier directly to specific brain targets. The company licenses its CED system and acquired Neuroinfuse drug delivery platform to pharmaceutical and biotech partners, and provides accompanying consultancy, preclinical support, and clinical trial services.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • More than 5,000 catheter infusions delivered to humans
+3 more records
Product overview1 text field

Neurochase offers a unified platform for targeted CNS drug delivery combining proprietary and acquired technologies. The core offering consists of the Neurochase CED Drug Delivery System - a scalable convection-enhanced delivery platform - integrated with the acquired Neuroinfuse™ system (bone-anchored transcutaneous port for chronic delivery) and specialized electrospun micro-catheters manufactured via VIVOLTA partnership. Supporting the technology portfolio are consultancy and training services for pre-clinical studies, clinical trials, and ongoing CNS drug delivery projects. The combined portfolio addresses both acute and chronic delivery needs across conditions including Parkinson's Disease, Huntington's Disease, brain tumors, and MND.

Product and service1 record
1Neurochase CED Drug Delivery System
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierFlagshipTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-11-20
Description

Acquisition of Renishaw Neuro Solutions’ key strategic device assets including the Neuroinfuse drug delivery system and all associated IP. The Neuroinfuse system comprises bone-anchored transcutaneous port for intermittent therapy administration over months or years. Deal creates premier global platform for targeted CNS drug delivery.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-11-13
Description

Long-term manufacturing partnership where VIVOLTA serves as exclusive electrospun component manufacturer for Neurochase’s micro-catheter delivery system. VIVOLTA first partnered with Neurochase in 2022 for product development and has been part of R&D team bringing material science expertise. VIVOLTA’s fully-automated MediSpin production system enables scalable manufacturing.

3Hamlet Pharma
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-18
Description

Joint development agreement to develop novel technology and methods to treat CNS tumors with Alpha1H. Collaboration involves developing new technology for delivery of Alpha1H to the leptomeninges for treatment of primary and secondary CNS tumors including glioblastomas. Primarily explores infusion in preclinical models.

neurochase.com
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2023-01-27
Description

Strategic collaboration to develop Neurochase’s proprietary delivery technology for use with selected gene therapies for rare diseases in CNS. Neurochase brings deep expertise in direct drug delivery technology to Spark’s leading AAV platform. Collaboration aims to improve targeted delivery of AAV gene therapy to neural structures using CED for diseases like Huntington’s Disease.

5CombiGene
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-06-28
Description

Preclinical study partnership to optimize administration of CG01 (gene therapy for drug-resistant focal epilepsy) using Neurochase injection device. Study evaluated injection volume and rate, providing valuable information for upcoming toxicology and biodistribution studies. CombiGene has exclusive collaboration and licensing agreement for CG01 with Spark Therapeutics.

neurochase.com
6Innervate Therapeutics
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

Exclusive license agreement for use of Neurochase devices and technology for GDNF gene therapy delivery. Innervate is developing GDNF gene therapies for Parkinson’s Disease and Motor Neuron Disease (MND/ALS). Neurochase’s technology enables scaling delivery and safe administration to large patient populations.

neurochase.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

ClearPoint Neuro provides MRI-guided intraparenchymal drug delivery systems for the CNS and is the closest direct competitor to Neurochase's CED platform; Neurochase's incoming CMO Jacqueline Keller was previously VP Marketing at ClearPoint Neuro, underscoring direct comparability.

TypeOthers
Description

Former division of Renishaw plc whose Neuroinfuse drug delivery assets Neurochase acquired in November 2025; historically a direct peer in CED/catheter-based CNS delivery and now a transferor of IP rather than an active competitor.

TypeBroad incumbent
Description

Brainlab offers broad neurosurgical navigation, planning, and surgical robotics used in stereotactic drug delivery procedures; comparable as a broader incumbent enabling the same surgical workflows Neurochase supports.

TypeBroad incumbent
Description

Medtronic operates drug delivery infusion systems (e.g., SynchroMed for intrathecal therapy) and deep brain stimulation infrastructure; a broad incumbent with overlapping CNS delivery/catheter capabilities, though not focused on CED intraparenchymal delivery.

TypeBroad incumbent
Description

Integra LifeSciences supplies a portfolio of neurosurgical instruments, catheters, and implantable devices used in CNS procedures, including components comparable to Neurochase's stereotactic and catheter workflow.

TypeBroad incumbent
Description

Abbott's neuromodulation business (formerly St. Jude) provides implantable neurostimulation devices including DBS, sharing the same neurosurgical implantation ecosystem and competing for hospital neurosurgery budgets alongside Neurochase's CED platform.

TypeOthers
Description

Spark Therapeutics (a Roche company) develops AAV gene therapies for CNS diseases and is Neurochase's flagship collaboration partner; comparable as an ecosystem participant that both consumes delivery platforms and validates demand for CED.

TypeOthers
Description

uniQure develops AAV-based gene therapies for CNS disorders (e.g., Huntington's) and represents a comparable ecosystem participant that would require targeted CNS delivery solutions like Neurochase's CED platform.

TypeOthers
Description

Voyager Therapeutics develops AAV gene therapies for severe neurological diseases (Parkinson's, ALS, Huntington's) and is a comparable ecosystem participant needing advanced CNS delivery capabilities similar to those Neurochase offers.

TypeOthers
Description

AviadoBio develops AAV gene therapies for frontotemporal dementia and ALS and collaborates with Neurochase (Prof. Gill on its SAB); an emerging gene therapy peer that represents both a customer and a comparable technology ecosystem participant.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Neurochase

CNS Drug Delivery Medical Devicesneurochase.com

Neurochase is a UK privately-held medical-device company that develops and licenses Convection Enhanced Delivery (CED) systems — proprietary micro-catheters and a bone-anchored port — to enable pharmaceutical and biotech partners to deliver gene, cell and conventional therapies across the blood-brain barrier for CNS disorders.

What Neurochase does

Neurochase Limited is a privately held UK medical-device company, founded in 2020 and headquartered in Cardiff with operational offices in Bristol and Glasgow, that develops and licenses Convection Enhanced Delivery (CED) platforms for targeted delivery of gene, cell and conventional therapies to the central nervous system. Its core product line centres on proprietary CED micro-catheters that use a pressure gradient to drive therapeutics past the blood-brain barrier and distribute them homogeneously through interstitial brain tissue, with cannula insertion achievable within 10 minutes per cannula and reflux control designed for accurate dosing. The platform is complemented by specialised electrospun micro-catheters manufactured in partnership with VIVOLTA using the MediSpin production system, and by the Neuroinfuse drug delivery system — a bone-anchored transcutaneous port acquired from Renishaw Neuro Solutions in November 2025 that enables intermittent, chronic therapy administration over months or years to deep brain targets.

The company monetises through three streams: licensing of its CED drug delivery technology and devices to pharmaceutical and biotech partners for use in their CNS clinical programs, expert consultancy on protocol development, surgical workflow optimisation and surgeon training for both preclinical studies and clinical trials, and future device sales for clinical trial use beginning in 2025. Its customer base consists of pharma and biotech sponsors developing gene and cell therapies for Parkinson's, Huntington's, MND/ALS, drug-resistant epilepsy, brain tumours and dementia, plus supporting CROs; named partners include Spark Therapeutics (Roche), CombiGene, Innervate Therapeutics, Hamlet Pharma and AviadoBio.

Neurochase is led by Founder and CSO Prof. Steven Gill, a pioneer of deep brain stimulation and the first clinical trial infusing GDNF directly into the brain, alongside CEO Sharon Kane, Medical Director Neil Barua and Chief Marketing Officer Jacqueline Keller. The company cites over 5,000 catheter infusions delivered to humans, a Phase 2 Parkinson's trial demonstrating neuro-restoration, and doubled progression-free survival in DIPG brainstem cancer as evidence of clinical credibility supporting its £1.5B addressable market claim for CNS drug delivery.

Neurochase firmographics

Firmographics
Name
Neurochase
Legal name
Neurochase Limited
Website
https://neurochase.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Short description
Neurochase is a UK privately-held medical-device company that develops and licenses Convection Enhanced Delivery (CED) systems — proprietary micro-catheters and a bone-anchored port — to enable pharmaceutical and biotech partners to deliver gene, cell and conventional therapies across the blood-brain barrier for CNS disorders.
Ownership category
akta.pro rank

Neurochase industry classification

Industry
Product category
CNS Drug Delivery Medical Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • CNS drug delivery
  • Convection Enhanced Delivery
  • Medical device manufacturing
  • Neuroscience consulting services
  • Micro-catheter production

Where Neurochase is headquartered

Location

Headquarters

HQ city
Bristol
HQ country
United Kingdom
HQ region
Europe

Offices3 records

Markets served

Neurochase business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

  1. Drug Delivery Device Licensing: Neurochase licenses its proprietary CED drug delivery technology and devices to pharmaceutical and biotech companies for use in their clinical programs. The company provides access to its technology platform including micro-catheters and delivery systems.
  2. Consultancy Services: Expert consultancy to biotech and pharma on direct delivery of therapies to the CNS. Services include protocol development, surgical workflow optimisation, and surgeon training. Pre-clinical support includes stereotactic equipment, devices and training to CROs.
  3. Device Sales: Sale and supply of CED drug delivery devices for clinical trials. From 2025, access to CED devices for clinical trial use. The company planned clinical trial for early 2026 using Neuroinfuse system.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Neurochase product offering

Product offering

Core offering

Neurochase develops and licenses proprietary Convection Enhanced Delivery (CED) technology for targeted intraparenchymal drug delivery to the central nervous system. Its flagship platform uses micro-catheters with pressure gradient-driven convection to push therapeutics through interstitial space, enabling homogeneous distribution past the blood-brain barrier directly to specific brain targets. The company licenses its CED system and acquired Neuroinfuse drug delivery platform to pharmaceutical and biotech partners, and provides accompanying consultancy, preclinical support, and clinical trial services.

Product overview

Neurochase offers a unified platform for targeted CNS drug delivery combining proprietary and acquired technologies. The core offering consists of the Neurochase CED Drug Delivery System - a scalable convection-enhanced delivery platform - integrated with the acquired Neuroinfuse™ system (bone-anchored transcutaneous port for chronic delivery) and specialized electrospun micro-catheters manufactured via VIVOLTA partnership. Supporting the technology portfolio are consultancy and training services for pre-clinical studies, clinical trials, and ongoing CNS drug delivery projects. The combined portfolio addresses both acute and chronic delivery needs across conditions including Parkinson's Disease, Huntington's Disease, brain tumors, and MND.

Differentiator

Problem solved

Functional benefit

Products and services

  • Neurochase CED Drug Delivery System

Quantifiable outcome

  • More than 5,000 catheter infusions delivered to humans
  • +3 more outcomes

Companies that use Neurochase

Customer profile

Named customers5 records

Segments2 records

Ideal customer profiles2 records

Neurochase technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Neurochase partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered flagship and core.

  • Renishaw Neuro SolutionsflagshipOEM/ Whitelabel/ Licensing Partner · 20 November 2025Acquisition of Renishaw Neuro Solutions’ key strategic device assets including the Neuroinfuse drug delivery system and all associated IP. The Neuroinfuse system comprises bone-anchored transcutaneous port for intermittent therapy administration over months or years. Deal creates premier global platform for targeted CNS drug delivery.
  • VIVOLTAcoreStrategic or Co-development Partner · 13 November 2024Long-term manufacturing partnership where VIVOLTA serves as exclusive electrospun component manufacturer for Neurochase’s micro-catheter delivery system. VIVOLTA first partnered with Neurochase in 2022 for product development and has been part of R&D team bringing material science expertise. VIVOLTA’s fully-automated MediSpin production system enables scalable manufacturing.
  • Hamlet PharmacoreStrategic or Co-development Partner · 18 January 2024Joint development agreement to develop novel technology and methods to treat CNS tumors with Alpha1H. Collaboration involves developing new technology for delivery of Alpha1H to the leptomeninges for treatment of primary and secondary CNS tumors including glioblastomas. Primarily explores infusion in preclinical models.
  • Spark Therapeutics (Roche Group)flagshipStrategic or Co-development Partner · 27 January 2023Strategic collaboration to develop Neurochase’s proprietary delivery technology for use with selected gene therapies for rare diseases in CNS. Neurochase brings deep expertise in direct drug delivery technology to Spark’s leading AAV platform. Collaboration aims to improve targeted delivery of AAV gene therapy to neural structures using CED for diseases like Huntington’s Disease.
  • CombiGenecoreStrategic or Co-development Partner · 28 June 2021Preclinical study partnership to optimize administration of CG01 (gene therapy for drug-resistant focal epilepsy) using Neurochase injection device. Study evaluated injection volume and rate, providing valuable information for upcoming toxicology and biodistribution studies. CombiGene has exclusive collaboration and licensing agreement for CG01 with Spark Therapeutics.
  • Innervate TherapeuticscoreOEM/ Whitelabel/ Licensing PartnerExclusive license agreement for use of Neurochase devices and technology for GDNF gene therapy delivery. Innervate is developing GDNF gene therapies for Parkinson’s Disease and Motor Neuron Disease (MND/ALS). Neurochase’s technology enables scaling delivery and safe administration to large patient populations.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Neurochase competitors and assessment

Company assessment

Direct peers

  • ClearPoint Neuro: ClearPoint Neuro provides MRI-guided intraparenchymal drug delivery systems for the CNS and is the closest direct competitor to Neurochase's CED platform; Neurochase's incoming CMO Jacqueline Keller was previously VP Marketing at ClearPoint Neuro, underscoring direct comparability.

Others

  • Renishaw Neuro Solutions: Former division of Renishaw plc whose Neuroinfuse drug delivery assets Neurochase acquired in November 2025; historically a direct peer in CED/catheter-based CNS delivery and now a transferor of IP rather than an active competitor.
  • Spark Therapeutics (Roche): Spark Therapeutics (a Roche company) develops AAV gene therapies for CNS diseases and is Neurochase's flagship collaboration partner; comparable as an ecosystem participant that both consumes delivery platforms and validates demand for CED.
  • uniQure: uniQure develops AAV-based gene therapies for CNS disorders (e.g., Huntington's) and represents a comparable ecosystem participant that would require targeted CNS delivery solutions like Neurochase's CED platform.
  • Voyager Therapeutics: Voyager Therapeutics develops AAV gene therapies for severe neurological diseases (Parkinson's, ALS, Huntington's) and is a comparable ecosystem participant needing advanced CNS delivery capabilities similar to those Neurochase offers.
  • AivadoBio: AviadoBio develops AAV gene therapies for frontotemporal dementia and ALS and collaborates with Neurochase (Prof. Gill on its SAB); an emerging gene therapy peer that represents both a customer and a comparable technology ecosystem participant.

Broad incumbents

  • Brainlab: Brainlab offers broad neurosurgical navigation, planning, and surgical robotics used in stereotactic drug delivery procedures; comparable as a broader incumbent enabling the same surgical workflows Neurochase supports.
  • Medtronic: Medtronic operates drug delivery infusion systems (e.g., SynchroMed for intrathecal therapy) and deep brain stimulation infrastructure; a broad incumbent with overlapping CNS delivery/catheter capabilities, though not focused on CED intraparenchymal delivery.
  • Integra LifeSciences: Integra LifeSciences supplies a portfolio of neurosurgical instruments, catheters, and implantable devices used in CNS procedures, including components comparable to Neurochase's stereotactic and catheter workflow.
  • Abbott Neuromodulation: Abbott's neuromodulation business (formerly St. Jude) provides implantable neurostimulation devices including DBS, sharing the same neurosurgical implantation ecosystem and competing for hospital neurosurgery budgets alongside Neurochase's CED platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Neurochase social profiles

Digital presence

Neurochase financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Neurochase leadership team

Management profile

Number of profiles

Profiles5 records

Neurochase funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Neurochase M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neurochase

What does Neurochase do?

Neurochase develops and licenses proprietary Convection Enhanced Delivery (CED) technology for targeted intraparenchymal drug delivery to the central nervous system. Its flagship platform uses micro-catheters with pressure gradient-driven convection to push therapeutics through interstitial space, enabling homogeneous distribution past the blood-brain barrier directly to specific brain targets. The company licenses its CED system and acquired Neuroinfuse drug delivery platform to pharmaceutical and biotech partners, and provides accompanying consultancy, preclinical support, and clinical trial services.

Is Neurochase a public or private company?

Neurochase is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Neurochase founded?

Neurochase was founded in 2020. It employs 11 to 50 people.

Where is Neurochase based?

Neurochase is headquartered in Bristol, United Kingdom, in the Europe region.

How does Neurochase make money?

Three revenue lines are on record. Drug Delivery Device Licensing is the primary driver. The others are consultancy Services and device Sales.

Who are Neurochase's main competitors?

ClearPoint Neuro is listed as a direct peer. Others are Renishaw Neuro Solutions, Spark Therapeutics (Roche), uniQure, Voyager Therapeutics and AivadoBio. Broad incumbents are Brainlab, Medtronic, Integra LifeSciences and Abbott Neuromodulation.

Does Neurochase have an API?

No public API is recorded for Neurochase.

What industry is Neurochase in?

Neurochase's product category is CNS Drug Delivery Medical Devices. Its primary akta.pro industry code is HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals. Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals